Abhishek Bachchan gears up for Kaalidhar Laapata's release on ZEE5, sharing cherished experiences from Bhopal shoot and promoting the film extensively.

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris ...

Bhopal: The Madhya Pradesh government on Saturday suspended seven engineers, including two chief engineers of the Public Works Department for the 'faulty design' of the new Rail Over Bridge in ...

Madhya Pradesh government suspends 7 engineers over bridge with 90-degree turn in Bhopal PTI | Published on: Jun 29, 2025 01:33 am IST Read this news in brief form ...

Have you ever seen a bridge take a sharp turn—like a perfect L-shape—right in the middle? That’s what just happened in Bhopal! Usually, builders—whether they’re architects or engineers ...

Bhopal’s 90-degree bridge: CM promises action against those responsible for ‘technical faults’ The 648-metre bridge in the Aishbagh area, which cost Rs 18 crore to build, was meant to eliminate long ...

The many wrong turns that led to Bhopal’s infamous right-angle bridge Railways spokesperson Naval Agarwal acknowledged that both departments had coordinated during the design phase and that Railways ...

Bhopal: Over 700 artists, dancers, poets, and filmmakers came together at Sadaneera Samagam, a six-day cultural conclave dedicated to raising awarenes.

AI company Ask Sage, which powers the Army's new generative AI system, announced a $10 million strategic partnership this week with the Army and the Pentagon's Chief Digital and Artificial ...

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million to gain access to the only postpartum depression pill approved in the United States.

Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a standard of care.

Sage Therapeutics has agreed to be acquired by Supernus Pharmaceuticals for up to $795 million, marking a “good end” to the biotech’s story, according to analysts. The deal comes about five months ...